ReviewJournal of translational medicine2015
Epidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancer.
Review in Journal of translational medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 55 citations in OpenAlex.
- Structure-guided optimization of N-sulfonylpiperidines toward potent multi-target anticancer agents.Scientific reports · 2026Article
- Anti-Metastatic Effects ofInternational journal of molecular sciences · 2025Article
- Astaxanthin promotes apoptosis by suppressing growth signaling pathways in HT-29 colorectal cancer cells.Medical oncology (Northwood, London, England) · 2025Article
- Advances in Targeted and Chemotherapeutic Strategies for Colorectal Cancer: Current Insights and Future Directions.Biomedicines · 2025Review
- RIZ2 at the crossroad of the EGF/EGFR signaling in colorectal cancer.Journal of translational medicine · 2023Article
- Correlation of tumor-associated macrophage infiltration in glioblastoma with magnetic resonance imaging characteristics: a retrospective cross-sectional study.Quantitative imaging in medicine and surgery · 2023Article
- Combination Therapy as a Promising Way to Fight Oral Cancer.Pharmaceutics · 2023Review
- Exploring the active components and potential mechanisms of Rosa roxburghii Tratt in treating type 2 diabetes mellitus based on UPLC-Q-exactive Orbitrap/MS and network pharmacology.Chinese medicine · 2023Article
- Precision and Accuracy of Receptor Quantification on Synthetic and Biological Surfaces Using DNA-PAINT.ACS sensors · 2023Article
- Therapeutic Role of Curcumin in Diabetes: An Analysis Based on Bioinformatic Findings.Nutrients · 2022Article
- A novel nanobody as therapeutics target for EGFR-positive colorectal cancer therapy: exploring the effects of the nanobody on SW480 cells using proteomics approach.Proteome science · 2022Article
- Growth Factors, PI3K/AKT/mTOR and MAPK Signaling Pathways in Colorectal Cancer Pathogenesis: Where Are We Now?International journal of molecular sciences · 2021Review
- Toward precision immunotherapy using multiplex immunohistochemistry and in silico methods to define the tumor immune microenvironment.Cancer immunology, immunotherapy : CII · 2021Review
- Identification and verification of three key genes associated with survival and prognosis of COAD patients via integrated bioinformatics analysis.Bioscience reports · 2020Observational
- HER2-HER3 Heterodimer Quantification by FRET-FLIM and Patient Subclass Analysis of the COIN Colorectal Trial.Journal of the National Cancer Institute · 2020Article
- Digital Receptor Occupancy Assay in Quantifying On- and Off-Target Binding Affinities of Therapeutic Antibodies.ACS sensors · 2020Article
- Soluble EGFR, a hepatokine, and adipsin, an adipokine, are biomarkers correlated with distinct aspects of insulin resistance in type 2 diabetes subjects.Diabetology & metabolic syndrome · 2020Article
- HER2Journal of cellular physiology · 2019Article
- Comparison of Biomarker Assays forClinical cancer research : an official journal of the American Association for Cancer Research · 2019Article
- Data-Independent Acquisition Mass Spectrometry To Quantify Protein Levels in FFPE Tumor Biopsies for Molecular Diagnostics.Journal of proteome research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
Abstract
The treatment of cancer is becoming more precise, targeting specific oncogenic drivers with targeted molecular therapies. The epidermal growth factor receptor has been found to be over-expressed in a multitude of solid tumours. Immunohistochemistry is widely used in the fields of diagnostic and personalised medicine to localise and visualise disease specific proteins. To date the clinical utility of epidermal growth factor receptor immunohistochemistry in determining monoclonal antibody efficacy has remained somewhat inconclusive. The lack of an agreed reproducible scoring criteria for epidermal growth factor receptor immunohistochemistry has, in various clinical trials yielded conflicting results as to the use of epidermal growth factor receptor immunohistochemistry assay as a companion diagnostic. This has resulted in this test being removed from the licence for the drug panitumumab and not performed in clinical practice for cetuximab. In this review we explore the reasons behind this with a particular emphasis on colorectal cancer, and to suggest a way of resolving the situation through improving the precision of epidermal growth factor receptor immunohistochemistry with quantitative image analysis of digitised images complemented with companion molecular morphological techniques such as in situ hybridisation and section based gene mutation analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.